Two medications dominate GLP-1 conversations in 2026: Ozempic (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly). Both are injectable medications prescribed for type 2 diabetes and weight management. Both produce significant weight loss. Both are available through telehealth.
But they're not the same medication — and the differences matter. Mounjaro uses a dual-receptor mechanism that semaglutide doesn't have. Head-to-head trials show different efficacy numbers. The cost and access pictures differ. This guide covers what the evidence actually says so you can have a more informed conversation with your prescriber.
The Quick Comparison
| Ozempic (semaglutide) | Mounjaro (tirzepatide) | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| FDA-approved for | Type 2 diabetes; cardiovascular risk reduction | Type 2 diabetes |
| Weight management form | Wegovy (semaglutide 2.4mg) | Zepbound (tirzepatide 15mg) |
| FDA approved (diabetes) | 2017 | 2022 |
| Max weekly dose | 2.0mg (Ozempic); 2.4mg (Wegovy) | 15mg (Mounjaro/Zepbound) |
| Avg. A1C reduction (peak dose) | ~1.5–1.8% | ~2.0–2.4% |
| Avg. weight loss (diabetes trials) | ~6–7 kg | ~9–12 kg |
| Avg. weight loss (obesity trials) | ~15% body weight (STEP 1) | ~20–22% body weight (SURMOUNT-1) |
| Brand list price | ~$850–$1,000/month | ~$1,000–$1,100/month |
| Compounded option | Widely available ($99–$450/mo) | Available through select providers ($150–$450/mo) |
| Telehealth availability | Widely available | Available; fewer platforms |
| Cardiovascular outcomes data | Yes (SOUL trial; SUSTAIN-6) | Limited (SURPASS-CVOT ongoing) |
How They Work Differently
This is the most important thing to understand about the Ozempic vs. Mounjaro comparison.
Ozempic: GLP-1 Receptor Agonist
Semaglutide works by activating GLP-1 receptors — mimicking the GLP-1 hormone that the gut produces naturally after eating. GLP-1 receptor activation:
- Stimulates insulin secretion in response to blood sugar
- Suppresses glucagon (which would otherwise raise blood sugar)
- Slows gastric emptying (food stays in the stomach longer, reducing appetite and post-meal glucose spikes)
- Acts on the hypothalamus to reduce appetite and food intake
This mechanism produces meaningful blood sugar control and significant weight loss for most patients. The STEP clinical trial program showed average weight loss of approximately 15% of body weight at the Wegovy dose (2.4mg/week) over 68 weeks.
Mounjaro: Dual GIP + GLP-1 Receptor Agonist
Tirzepatide activates two receptors — GLP-1 (same as semaglutide) plus GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism is the core reason tirzepatide generally outperforms semaglutide in clinical trials.
GIP receptor activation provides several additional effects:
- Enhanced insulin secretion beyond GLP-1 alone
- Additive effects on appetite suppression through different CNS pathways
- Potential improvements in lipid metabolism
The combination produces stronger glycemic control and greater weight loss than GLP-1 alone — though the precise contribution of each receptor pathway is still being studied.
Weight Loss Evidence
Diabetes Population Trials
| Trial | Comparison | Weight Loss Difference |
|---|---|---|
| SURPASS-2 | Tirzepatide 5/10/15mg vs. Semaglutide 1.0mg | Tirzepatide: −7.6/−9.3/−11.2 kg vs. Semaglutide: −5.7 kg |
| SURMOUNT-5 (head-to-head, obesity doses) | Tirzepatide 10/15mg vs. Semaglutide 2.4mg | Tirzepatide: 20.2% vs. Semaglutide: 13.7% body weight |
SURPASS-2 — the key head-to-head comparison in people with type 2 diabetes — showed tirzepatide outperformed semaglutide 1.0mg on both A1C reduction and weight loss at all three dose levels.
SURMOUNT-5 — published in 2025, the first head-to-head trial using weight management doses — confirmed tirzepatide's greater weight loss at maximum doses: 20.2% of body weight vs. 13.7% for semaglutide 2.4mg (Wegovy) over 72 weeks.
Weight Management Population Trials
| Trial | Drug | Average Weight Loss |
|---|---|---|
| STEP 1 (Wegovy) | Semaglutide 2.4mg | −14.9% body weight |
| SURMOUNT-1 (Zepbound) | Tirzepatide 15mg | −20.9% body weight |
These are separate trials with different populations, so direct comparison has limitations — but the magnitude difference is consistent with the head-to-head data. Tirzepatide produces approximately 5–7 percentage points more weight loss than semaglutide at peak doses.
What this means practically: For a 250-pound patient:
- Semaglutide (Wegovy): average loss of ~37 lbs
- Tirzepatide (Zepbound): average loss of ~52 lbs
These are averages. Individual response varies significantly, and some patients respond better to semaglutide. Neither medication guarantees results, and both require sustained use — the STEP-4 trial showed weight returns after discontinuation.
A1C Reduction for Type 2 Diabetes
Both medications are highly effective for blood sugar control. SURPASS-2 showed:
| Medication | A1C Reduction |
|---|---|
| Tirzepatide 5mg | −2.01% |
| Tirzepatide 10mg | −2.24% |
| Tirzepatide 15mg | −2.30% |
| Semaglutide 1.0mg | −1.86% |
Tirzepatide's advantage on A1C is meaningful but both are substantially above the clinical threshold for meaningful glycemic improvement. For most patients with type 2 diabetes, either medication would significantly improve blood sugar control.
Side Effects: What's Similar and What's Different
What's the Same
Both medications cause similar GLP-1-driven side effects, which peak during dose escalation:
- Nausea — most common with both; typically peaks in weeks 2–6 and reduces as the body adjusts
- Vomiting, diarrhea, constipation — GI effects that vary by individual
- Decreased appetite — the intended effect, also listed as a side effect
- Fatigue — especially during early weeks of titration
Both carry the same serious warnings:
- Pancreatitis — rare; discontinue if symptoms occur
- Gallbladder disease — increased risk with rapid weight loss
- Thyroid C-cell tumor warning — boxed warning on both based on rodent studies; not established in humans
- Contraindicated in pregnancy
Where They Differ
Nausea: Clinical trial data shows broadly comparable GI tolerability between the two medications. Some prescribers report anecdotally that tirzepatide's higher-dose titration can cause slightly more nausea — but head-to-head trial data doesn't definitively show one as better tolerated than the other.
Cardiovascular outcomes data: Ozempic/semaglutide has more established cardiovascular data. The SUSTAIN-6 and SELECT trials confirmed cardiovascular risk reduction with semaglutide. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. For patients whose primary concern is cardiovascular risk reduction, semaglutide's more mature evidence base is relevant.
Injection site reactions: Both use subcutaneous injections with similar injection pen mechanisms. Injection site reactions are rare with either medication.
Cost Comparison
Brand-Name Pricing
Both medications are expensive at list price:
| Medication | Typical List Price | Notes |
|---|---|---|
| Ozempic (0.5–2.0mg) | ~$850–$1,000/month | Diabetes indication |
| Wegovy (2.4mg) | ~$1,300–$1,500/month | Weight management |
| Mounjaro (2.5–15mg) | ~$1,000–$1,100/month | Diabetes indication |
| Zepbound (2.5–15mg) | ~$1,050–$1,200/month | Weight management |
Manufacturer savings cards can reduce costs for commercially insured patients not using government programs.
Compounded Access Through Telehealth
This is where the practical cost picture becomes more accessible for out-of-pocket patients.
Compounded semaglutide (Ozempic's active ingredient):
| Provider | Monthly Cost |
|---|---|
| Belle Health | $119/mo |
| Ro | $149/mo |
| Henry Meds | $149/mo |
| Ivim Health | $150/mo |
| Found | $159/mo |
| Hims | $199/mo |
Compounded tirzepatide (Mounjaro's active ingredient): Compounded tirzepatide became available through select telehealth providers in 2024–2025, typically priced at $150–$450/month. Availability varies significantly by state and provider. Some pharmacies provide it at similar or slightly higher cost than compounded semaglutide.
The access difference: Compounded semaglutide is available through 15+ major telehealth platforms. Compounded tirzepatide is available through fewer platforms, and availability changed significantly following FDA enforcement actions against certain compounding pharmacies in 2024. Check current availability directly with providers.
Insurance Coverage
| Drug | Typical Coverage |
|---|---|
| Ozempic | Covered by most commercial plans for type 2 diabetes; variable for weight management |
| Mounjaro | Covered by many plans for type 2 diabetes since 2023 label; variable for weight management |
| Wegovy | Weight management coverage has improved but varies widely |
| Zepbound | Weight management coverage growing; many plans still require PA |
Both medications typically require prior authorization for weight management use. Some insurers require step therapy (trying a lower-cost option first). Your benefits manager or plan formulary is the authoritative source on coverage.
Telehealth Access
Semaglutide (Ozempic): Widespread Availability
Compounded semaglutide is available through most major GLP-1 telehealth platforms:
- Ro, Henry Meds, Found, Hims, LifeMD, Belle Health, Ivim Health, Calibrate, and more
- Ships to most U.S. states
- Asynchronous or video consultation typically available
- Monthly pricing well-established
Tirzepatide (Mounjaro): Growing But More Limited
Compounded tirzepatide is available through select telehealth providers. The market has evolved significantly:
- Available through some major platforms (Ro, LifeMD, Hims, others)
- State availability varies; check provider's current availability map
- Pricing has stabilized at $150–$450/month at most platforms
If your priority is broadest telehealth access and lowest out-of-pocket cost, semaglutide is currently the more accessible option. If you want maximum weight loss potential and cost is less of a concern, tirzepatide may be worth the additional access complexity.
How to Choose: A Decision Framework
Choose Ozempic/Semaglutide if:
- Cost is a primary concern and you want the most affordable telehealth option
- You want the broadest platform selection and most established telehealth market
- You have established cardiovascular disease and value the mature cardiovascular outcomes data
- You're already on semaglutide and it's working well — switching for marginal additional weight loss may not be warranted
- Your prescriber is more experienced with semaglutide
Choose Mounjaro/Tirzepatide if:
- Maximum weight loss is your primary goal and the head-to-head data difference matters to you
- Your insurance covers tirzepatide and access isn't a barrier
- You have type 2 diabetes with stubborn A1C despite semaglutide
- Your prescriber specifically recommends tirzepatide based on your metabolic profile
A note on switching: Some patients who have plateaued on semaglutide are switched to tirzepatide and report renewed weight loss. This is an active area of clinical practice, not yet well-studied in RCTs. If you're on semaglutide and have plateaued, ask your provider whether switching is appropriate for your situation.
What Our Provider Database Shows
TeleHealthAlly's provider comparison covers 17+ GLP-1 telehealth providers across the U.S. Both semaglutide and tirzepatide are available through multiple platforms. Filter by medication, state, and pricing on our full provider comparison to see current options in your area.
Frequently Asked Questions
Does Mounjaro cause more weight loss than Ozempic?
Yes, in head-to-head and parallel clinical trials, tirzepatide (Mounjaro/Zepbound) consistently produces more weight loss than semaglutide (Ozempic/Wegovy) at comparable doses. The SURMOUNT-5 trial — the first direct head-to-head comparison — showed tirzepatide 15mg produced an average of 20.2% body weight reduction vs. 13.7% for semaglutide 2.4mg (Wegovy) over 72 weeks. However, individual response varies significantly, and both medications produce clinically meaningful weight loss for most patients.
Is Mounjaro or Ozempic better for type 2 diabetes?
Both are FDA-approved for type 2 diabetes and highly effective. SURPASS-2, a head-to-head trial, showed tirzepatide (Mounjaro) outperformed semaglutide (Ozempic) at all doses on A1C reduction and weight loss. Tirzepatide's dual GIP/GLP-1 mechanism provides additive glycemic control. However, Ozempic has a longer real-world track record (approved 2017 vs. 2022) and broader cardiovascular outcomes data. For most patients with type 2 diabetes, either is an appropriate choice — the decision often comes down to coverage, cost, and individual prescriber experience.
Can I get Mounjaro or Ozempic through telehealth?
Yes — both are available through telehealth, but with important differences. Semaglutide (Ozempic's active ingredient) is widely available through GLP-1 telehealth platforms as a compounded injectable for $99–$450/month. Tirzepatide (Mounjaro's active ingredient) is also available compounded through select telehealth providers, typically at $150–$450/month. Coverage varies by state and provider. Use our GLP-1 provider comparison tool to find providers offering the specific medication in your state.
What are the side effect differences between Ozempic and Mounjaro?
Both medications share a similar GLP-1-driven side effect profile: nausea, vomiting, diarrhea, constipation, and decreased appetite are the most common complaints for both. Mounjaro (tirzepatide) may cause slightly more nausea at higher doses given its additional GIP receptor activity, but clinical trial data shows comparable overall tolerability between the two. Serious risks — pancreatitis, gallbladder disease, thyroid C-cell tumor warnings — apply to both medications.
Compare GLP-1 telehealth providers offering semaglutide and tirzepatide — filter by medication, state, and price — on our provider comparison page.